Background: Telavancin is approved in the USA and Canada for the treatment of Gram-positive complicated skin and skin structure infections (cSSSIs) based on the results of the Phase 3 Assessment of TeLAvancin in complicated Skin and skin structure infections (ATLAS) trials, which demonstrated non-inferiority of telavancin to vancomycin.
Introduction
Until recently, the prevalence of infections due to methicillinresistant Staphylococcus aureus (MRSA) had been increasing in both hospitals and communities. 1 -5 Surveillance in Europe has shown that rates of MRSA have slightly declined in bloodstream infections, from 21.5% in 2002 to 19 .7% in 2009. 5 Furthermore, in the USA the incidence of central line-associated bloodstream infections (CLABSIs) due to MRSA has decreased. Despite these changes, the proportion of methicillin resistance in S. aureus isolated from patients with CLABSI has risen above 60% in the USA 6 and is still significant in many European countries. 7 In addition, in some regions (particularly in the USA), community-associated MRSA (CA-MRSA) strains carrying Panton-Valentine leucocidin (PVL) toxin genes are now the most common cause of complicated skin and skin structure infections (cSSSIs), particularly abscesses and infective cellulitis. 8, 9 Glycopeptides, particularly vancomycin, are the mainstay of antibacterial therapy for severe infections caused by MRSA. However, resistance to this class of antimicrobials has emerged. 10 -13 In addition, an increase in vancomycin MICs has been reported among MRSA strains deemed susceptible to vancomycin. 14 Resistance to available agents such as daptomycin and linezolid has also been described in clinical MRSA isolates. 15, 16 # The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2012; 67: 1496 -1502 doi:10.1093/jac/dks081 Advance Access publication 13 March 2012 Telavancin is an intravenous lipoglycopeptide with a dual mechanism of action that is rapidly bactericidal against many Gram-positive cocci, including MRSA. 17, 18 Telavancin is active against vancomycin-intermediate and fully resistant strains of S. aureus (VISA and VRSA, respectively). 19 -21 Based on the results of two large, randomized, double-blind clinical trials [the Assessment of TeLAvancin in complicated Skin and skin structure infections (ATLAS) studies], telavancin is approved in the USA and Canada for the treatment of adult patients with cSSSIs due to susceptible Gram-positive pathogens. 22 With the exception of surgical wound infections, 23 the ATLAS trial results for individual types of cSSSIs have not been published. Herein we describe the results of a post hoc analysis of the ATLAS studies to assess telavancin efficacy in patients with different types of cSSSIs, including MRSA infections and PVL-positive MRSA infections.
Patients and methods

Study design
The ATLAS studies were two identical, randomized, double-blind, activecontrolled, parallel-group, Phase 3 clinical studies (ClinicalTrials.gov identifiers NCT00091819 and NCT00107978) conducted between January 2005 and June 2006 at 129 study sites in 21 countries. Studies were approved by the institutional Review Board or Ethics Committee for each study site, and written informed consent was obtained from all patients.
Patient population
Details regarding inclusion and exclusion criteria are described elsewhere. 22 Briefly, patients were eligible if they were men or non-pregnant women aged ≥18 years, with a diagnosis of cSSSI (deep extensive cellulitis, major abscess requiring surgical drainage, or infected wound, ulcer or burn) caused by a suspected or confirmed Gram-positive organism that warranted ≥7 days of parenteral antibacterial therapy. Baseline pathogens must have been susceptible to the comparator drug, vancomycin. Purulent drainage/collection or at least three signs or symptoms of infection were also required. Patients were excluded if they had received .24 h of prior antibiotic therapy (unless the pathogen was resistant or the therapy failed), osteomyelitis, necrotizing fasciitis, chronic diabetic foot ulcers, gangrene, burns involving .20% of the body surface, neutropenia (,500 cells/mm 3 ), uncompensated heart failure or corrected QT interval (QTc) .500 ms.
Antimicrobial therapy
Patients were randomized to receive either intravenous telavancin (10 mg/kg every 24 h) or vancomycin (1 g every 12 h) in a 1 : 1 ratio. Vancomycin dosing could be adjusted for body weight and/or renal function in accordance with local standard practice while maintaining the study blind to those investigators involved in clinical evaluations. In patients with moderate to severe renal insufficiency, the dose of telavancin was adjusted based on the estimated creatinine clearance (CL CR ): 7.5 mg/kg every 24 h for patients with CL CR 30 -50 mL/min and 10 mg/kg every 48 h for patients with CL CR ,30 mL/min. 22 Study medications were administered for 7-14 days. Switching to other oral antimicrobials was not permitted. The addition of aztreonam and/or metronidazole was allowed in patients with proven or suspected polymicrobial infections involving Gram-negative pathogens and/or anaerobes.
Clinical and microbiological evaluations
Clinical assessments were conducted at baseline and daily through the end-of-therapy (EOT) evaluation. Test-of-cure (TOC) evaluation was conducted 7-14 days after the last dose of study medication. At each evaluation, investigators assessed the signs, symptoms and extent of the infection, surgical procedures, adverse events and concomitant medications.
Microbiological specimens for Gram staining and culture were obtained from all patients at baseline. These procedures were repeated at TOC only if purulent drainage or other evidence of continuing infection was present. Swab cultures were not permitted. Confirmatory identification of the pathogens and susceptibility testing were conducted at a central laboratory (Covance Clinical Laboratories, Indianapolis, IN, USA).
Responses
Clinical response was determined by the study site investigator, and was classified as cure, failure or indeterminate at TOC. Cure was defined as resolution of clinically significant signs and symptoms associated with the cSSSI, or improvement to the extent that the infectious process had been controlled and no further antimicrobial therapy was necessary. Failure was defined as an inadequate response to study therapy, which included patients who underwent more than two surgical procedures that were more significant than routine debridement after the initiation of study medication. An indeterminate response was defined as the inability to determine outcome (e.g. patients receiving a non-protocol potentially effective antibiotic or patients who did not have their EOT or TOC visits within the protocol-specified windows).
Analysis groups
Definitions of the analysis groups reported here are as follows: (i) all treated (AT), patients with a confirmed cSSSI diagnosis who received at least one dose of study medication; (ii) clinically evaluable (CE), patients in the AT group who complied with all exclusion/inclusion criteria and had a clinical response of either cure or failure at TOC (patients were excluded from this subgroup if they had only Gram-negative pathogen(s) or had a polymicrobial infection with a Gram-negative pathogen resistant to aztreonam isolated at baseline); and (iii) microbiologically evaluable (ME), patients in the CE subgroup who also had a baseline Gram-positive pathogen recovered from baseline cultures. Safety was evaluated in all patients who received at least one dose of study medication (safety population).
Statistical analysis
The results described herein are a post hoc analysis of subgroups from the pooled ATLAS studies. ATLAS 1 and 2 were designed with prespecified analyses for each trial individually, followed by a pooled-studies analysis of the subgroup of patients with MRSA infection. 22 The primary efficacy endpoint was clinical response at TOC. In the current post hoc pooled analysis of the two ATLAS studies we explored the cure rates of telavancin in (i) patients with different types of cSSSIs, (ii) patients with different types of cSSSIs involving MRSA, and (iii) patients infected with PVL-positive strains of MRSA.
Two-sided 95% CIs for the difference in response rates (telavancin2 vancomycin) were calculated using asymptotic methods, stratifying on study. In small-sample situations, the small-sample adjustment of Agresti and Caffo 24 was used. The CIs were not adjusted for multiplicity of comparisons in these exploratory analyses.
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Results
A total of 1867 patients were randomized and received at least one dose of study medication in the ATLAS 1 and 2 trials. 22 In accordance with guidance from the US FDA, patients from three sites (n¼ 73) were excluded from the efficacy analysis, leaving a total of 1794 AT patients (telavancin 884, vancomycin 910; Table 1 ). Approximately two-thirds of patients were enrolled in the USA. Eighty percent of AT patients were CE.
The baseline characteristics of the pooled ATLAS 1 and 2 study cohorts have been published elsewhere. 22 For the 1794 patients in the AT group of the current post hoc analysis, treatment groups were comparable in terms of both demographic and clinical variables ( Table 2 ). There was a slight predominance of men (57%), most patients were white (77%) and most were hospitalized at study entry (70%). The mean age of patients was 49 years. The most common conditions predisposing patients to cSSSIs were diabetes and trauma. Major abscesses (43%) and cellulitis (36%) were the most common types of infections. Almost two-thirds of patients with abscesses had lesions .50 cm 2 . MRSA, the most common baseline pathogen, was isolated in 563 (55%) ME patients ( Table 3 ). The majority of MRSA strains that were tested from ME patients carried PVL genes [447/529 (84%)].
Among CE patients, cure rates for telavancin and vancomycin were comparable across all types of infection (Table 4) . Cure rates in patients with abscesses were 91% for telavancin and 90% for vancomycin (95% CI for the difference 23.6 to 5.7). In patients with cellulitis, cure rates were 87% and 88% for the telavancin and vancomycin groups, respectively (95% CI for the difference 26.2 to 5.2). Cure rates were also similar between the two groups in those patients with wound infections, infected burns or infected ulcers.
Cure rates across different types of cSSSI patients infected with MRSA were also similar between the treatment groups (Table 5 ). In patients infected with PVL-positive strains of MRSA Percentage of CE patients. Stryjewski et al.
(across all infection types), cure rates were 93% for telavancin and 90% for vancomycin (95% CI for the difference 22.2 to 8.2). The most common treatment-emergent adverse events in patients with major abscesses, infective cellulitis and wound infections (.90% of safety population) are displayed in Table 6 . Except for taste disturbance, mild nausea, vomiting and urine abnormalities (foamy urine) in the telavancin group, adverse events were of similar type and severity between treatment arms. The results of the overall ATLAS safety (including adverse events and laboratory abnormalities) and tolerability analyses have been published previously. 22 
Discussion
Telavancin was clinically active across the different types of cSSSIs examined in this sub-analysis of the ATLAS clinical programme. Together with the previously published primary results of the ATLAS studies, which demonstrated the noninferiority of telavancin to vancomycin for the treatment of cSSSIs, 22 the results of the current post hoc analysis indicate that telavancin appears effective for the treatment of patients with specific types of cSSSIs, including those patients with abscesses or infective cellulitis. Given the non-inferiority design of the ATLAS studies and the fact that baseline pathogens had to have been susceptible to the comparator drug (vancomycin), the similar results in each treatment group are not unexpected.
Telavancin was a useful adjunct in the treatment of patients with major abscesses. While adequate drainage is essential in the treatment of abscesses, 25 concomitant antibiotic therapy is also important in patients with major abscesses who require hospitalization or who have diabetes. 9 Studies suggesting high cure rates with drainage alone and no antibiotics have usually Table 3 . Most common pathogens isolated from the primary infection site (ME patients with major abscesses, infective cellulitis and wound infections)
Major abscess
Cellulitis Wound infection (13) 40 (16) 11 (9) 13 (9) 11 (12) 12 (14) 1 (25) 58 (22) 50 (41) 69 (46) 35 (38) 26 (31) Enterococcus faecalis 3 (1) 6 (2) 8 (7) 13 (9) 6 (7) 4 (5) Streptococcus agalactiae 10 (4) 9 (3) 4 (3) 6 (4) 3 (3) 1 (1) Streptococcus anginosus 9 (4) 5 (2) 1 (,1)
6 (2) 6 (2) 10 (8) 15 (10) 3 (3) 2 (2) Gram-negative pathogens 14 (5) 17 (7) 21 (17) 14 (9) 12 (13) 10 (12) Enterobacter cloacae 1 (,1)
5 (2) 6 (2) 3 (2) 4 (3) 3 (3) 3 (4) Pseudomonas aeruginosa 0 (0) 1 (,1) 8 (7) 3 (2) 2 (2) 2 (2) a MRSA MIC of vancomycin was not available for 14 patients in the telavancin group and 15 patients in the vancomycin group (considering all types of infection). 26 and/or trial populations with low rates of diabetes. 27 For example, a recent trial in patients with abscesses in an area with a high risk of CA-MRSA compared drainage plus oral cephalexin versus placebo. Although cure rates were high in both treatment arms, the mean surface area of lesions was 19 cm 2 and ,5% of patients were diabetic. 27 In contrast, a study in patients with skin and skin structure infections due to CA-MRSA in which approximately two-thirds of the patients had abscesses indicated a beneficial effect of adequate antibiotic therapy among these patients. 28 Patients enrolled in the ATLAS studies required intravenous therapy for ≥7 days, were often diabetic, were hospitalized at enrolment and had large lesions, and many had MRSA infections. These findings suggest that adjunct therapy with telavancin is useful in the treatment of patients with large skin/soft tissue abscesses.
Patients with infective cellulitis, one of the most common types of cSSSIs, had similar cure rates whether treated with (9) 38 (11) 20 (6) 17 (12) 11 (9) Insomnia 48 (12) 43 (11) 24 (7) 32 (9) 14 (10) 8 (6) Urine abnormality 79 (20) 21 (5) 31 (9) 4 (1) 11 (8) 1 (,1) Constipation 38 (10) 28 (7) 33 (10) 22 (6) 19 (13) 7 (6) Pruritus 27 (7) 62 (15) 16 (5) 33 (9) 6 (4) 21 (17) Diarrhoea 24 (6) 31 (8) 24 (7) 32 (9) 13 (9) 11 (9) Dizziness 24 (6) 26 (6) 19 (6) 16 (5) 10 (7) 10 (8) Pruritus generalized 14 (4) 35 (9) 11 (3) 7 (2) 5 (3) 5 (4) Infusion site pain 21 (5) 21 (5) 13 (4) 14 (4) 6 (4) 4 (3) Rash 12 (3) 21 (5) 14 (4) 15 (4) 5 (3) 5 (4) Fatigue 22 (6) 20 (5) 14 (4) 7 (2) 4 (3) 3 (2) Rigors 16 (4) 10 (2) 14 (4) 5 (1) 8 (6) 4 (3) a No patients from any site were excluded from the safety analyses.
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telavancin or vancomycin. Because it is often associated with comorbid conditions, infective cellulitis frequently requires hospital admission and parenteral antibiotics for effective treatment. 29, 30 With the exception of purulent infections, obtaining microbiological diagnosis in patients with infective cellulitis is difficult. In the ATLAS studies 117 ME patients had infective cellulitis due to MRSA, allowing a rigorous assessment of the clinical effect of telavancin in this group of patients. Such a demonstration of efficacy is particularly relevant given the epidemic of CA-MRSA, in which abscesses and cellulitis are the most common types of cSSSIs. 9 Cure rates obtained with telavancin were also comparable to those observed with vancomycin in the treatment of patients with specific types of cSSSIs due to MRSA and methicillinsusceptible S. aureus (MSSA), including those patients infected with PVL-positive strains. Although PVL genes are not thought to be the primary determinant of outcome in patients with cSSSIs, 31 the presence of these genes is a useful marker for identifying CA-MRSA. 32 These results indicate that telavancin was useful in the treatment of patients with cSSSIs due to CA-MRSA.
This analysis has limitations. First, the ATLAS studies were not powered to prove the non-inferiority of telavancin to vancomycin for each type of cSSSI. Consequently, the results described herein should be interpreted as a post hoc analysis. However, the large number of patients and the consistency found across the different infection types in the present analysis indicate that the results of this study are robust and support the concept that telavancin is effective in treating a variety of different types of cSSSIs. Second, although efficacy was explored in patients with infected ulcers and infected burns, the sample size of these subgroups did not support further analyses. Third, patients with chronic diabetic ulcers were excluded from the ATLAS studies. Therefore, no conclusion can be made about the activity of telavancin in this infection type.
In summary, the positive outcome in the overall population was further demonstrated in the infection type subsets where there were sufficient patients to draw a conclusion. In addition, telavancin and vancomycin have similar cure rates in patients with specific types of cSSSIs due to MRSA, including those patients infected with strains of CA-MRSA. We wish to thank the ATLAS Study Group. 22 In particular, we wish to pay tribute to the work of Dr Lala M. Dunbar, who passed away prior to publication of this manuscript.
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